Kaynes or Syrma? Analysts Decode Fast-Growing EMS Stocks

Spread love

By S. JHA

India’s EMS boom is accelerating, but investors are now split between high-growth Kaynes Technology and steady performer Syrma SGS. After the latest Q4 results, which stock looks stronger?

Mumbai, May 15, 2026 — India’s Electronics Manufacturing Services (EMS) sector continues to ride the “China Plus One” wave, government PLI incentives, and rising domestic electronics demand. Among listed EMS players, two companies often compared by investors are Kaynes Technology and Syrma SGS Technology.

But after the latest quarterly results, the gap between the two appears to be widening — at least in the short term.

Kaynes: High Growth Story Faces Execution Questions

For the last two years, Kaynes Technology has been among the market’s favorite EMS stocks because of its ambitious expansion into semiconductor packaging (OSAT), PCB manufacturing, and higher-margin ODM businesses. Analysts have viewed the company as a potential long-term electronics champion.

However, the latest Q4 FY26 numbers as reported earlier by The Raisina Hills triggered a sharp negative reaction. Kaynes reported a 22% decline in quarterly profit despite revenue rising 26% year-on-year. Margin compression and weaker-than-expected execution rattled investors.

Brokerages including JPMorgan and Nuvama reportedly downgraded the stock after concerns emerged over: slowing profitability, pressure on balance-sheet metrics, and risks around ambitious guidance delivery.

The stock consequently plunged nearly 19% in a single trading session, while further sliding down almost two per cent on Friday to close at ₹3276. The stock had at its peak touched almost the level of ₹8000.

Still, long-term bulls argue that Kaynes remains strategically ahead in technology depth. Its OSAT facility and PCB expansion could become major revenue engines over the next few years. S&P Global recently noted that these projects may significantly lift future sales.

The issue for investors is valuation versus execution. Kaynes historically traded at extremely rich earnings multiples because markets priced in near-perfect growth. Once growth moderates or margins shrink, the de-rating can be brutal.

Syrma SGS: Quietly Building a More Stable Growth Story

In contrast, Syrma SGS has recently delivered what investors typically reward most — predictable growth with improving profitability.

The company reported: 56% revenue growth in Q4 FY26, 67% jump in quarterly profit, and nearly 87% rise in annual PAT.

Unlike Kaynes, Syrma’s earnings momentum appears supported by improving operational efficiency and relatively stronger balance-sheet discipline. Analysts tracking the company have highlighted margin expansion and debt reduction after its QIP fundraising.

Another advantage is diversification. Syrma is increasingly expanding into: automotive electronics, industrial electronics, defence systems, railways, medical electronics, and exports.

Its defence electronics ambitions are especially interesting. The company recently indicated visibility for nearly ₹400 crore in defence-related revenue following acquisitions in navigation and communication systems per a report in The Times of India.

Moreover, Syrma’s planned PCB manufacturing investments and export growth strategy align well with India’s electronics manufacturing push. The stock hit a 52-week high of ₹1188, while it closed at ₹1010 on Friday.

Which Stock Should Investors Prefer?

The answer depends on risk appetite. Investors preferring aggressive growth: Kaynes may still appeal to investors willing to tolerate volatility for potentially outsized long-term gains. If its semiconductor and PCB bets succeed, the company could evolve into a much larger integrated electronics platform.

But investors must recognize that Kaynes is now entering a phase where execution risks are higher, capital expenditure requirements are rising, and valuation comfort has diminished.

Investors preferring stability: Syrma SGS currently appears better positioned on a risk-reward basis.

The company is showing: stronger earnings momentum, improving operational efficiency, more balanced valuations, and broader diversification across sectors.

At this stage of the EMS cycle, many investors may prefer consistency over aggressive projections.